EUCTR2011-004183-29-GB进行中（未招募）1 期
A randomised, placebo-controlled trial to investigate the effectiveness of an antimicrobial product in the elimination of Staphylococcus aureus colonisation from the anterior nares of adult subjects with atopic eczema. A proof of concept study (the NASSAELIM pilot). - An antimicrobial product for removal of bacteria from inside the nose.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The principal inclusion criteria are as follows:
- •i)Adult subjects (aged 16 years and above) not meeting any of the exclusion criteria.
- •ii)Subjects diagnosed by the Investigator as having atopic eczema, as defined as;
- •a)Have an itchy skin condition within the past 12 months
- •plus at least three of the following:
- •b)History of flexural involvement
- •c)History of generally dry skin
- •d)Personal history of asthma or allergic rhinitis
- •e)Visible dermatitis involving skin creases
- •f)First onset of signs and symptoms as a child
- •iii)Subjects testing positive for the presence of Staphylococcus aureus in the anterior nares when swabbed on Day -7, with a colony count of greater than 1000 Colony Forming Units (CFU).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 8
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •The following subjects will be excluded from taking part in the study:
- •i)Subjects with a history of intolerance or skin sensitivity to any of the ingredients of the two IMPs.
- •ii)Subjects with infected eczema or any other infected skin condition.
- •iii)Subjects currently taking, or having taken within the 4 weeks prior to the study start (Day -7), any oral antibiotics, oral corticosteroids or oral immunosuppressants for acute conditions. Subjects that are taking low dose oral corticosteroids for long term, chronic conditions (such as arthritis, inflammatory bowel conditions) or using inhaled corticosteroids (for asthma or COPD) long term will be eligible if in the opinion of the Investigator their medication will not have any impact on the results of the trial.
- •iv)Subjects who are currently using or have used any topical antibiotics in the nose in the two weeks prior to the study start (Day -7).
- •v)Subjects who in the Investigator’s opinion would find nasal administration of the test IMP unacceptable or impracticable.
- •vi)Subjects with nasal piercings.
- •vii)Subjects with current allergic rhinitis, symptoms of cold or flu, nasal polyps or any damage to the nose.
- •viii)Subjects with systemic diseases which, in the opinion of the Investigator, may adversely influence their participation in the trial.
- •ix)Subjects who have received any unlicensed medicine within the last 30 days or who are scheduled to receive an investigative drug other than the study medication during the period of the study.
- •x)Subjects with current or recent heavy use of recreational drugs in the nose that may affect the nasal morphology.
- •xi)Female subjects who are pregnant or lactating (although there are no particular safety concerns in these subject groups, it is generally inappropriate for them to participate in clinical trials without overriding justification). Pregnancy testing is not deemed necessary and therefore will not be performed.
- •xii)Subjects considered unable or unlikely to adhere to the treatment regimen or attend the necessary follow-up visits.
- •xiii)Subjects with another member of the household already enrolled in the study, regardless of whether they have completed their participation. This is to avoid possible mix up between assigned IMPs and to avoid any subjects from seeing both of the study products which could affect blinding.
- •xiv)Subjects with planned elective surgery in the next 8 weeks that may require nasal decolonisation.
- •xv)Employees of Simbec, Dermal Laboratories or an immediate family member (partner, offspring, parents, siblings or sibling’s offspring) of such employees.
研究者
相似试验
已完成
不适用
The effect of vitamin D supplementation on muscle strength and function in UK South Asian womeNutritional, Metabolic, EndocrineVitamin D deficiencyISRCTN41610200The University of Sheffield100
进行中（未招募）
不适用
A randomized placebo-controlled trial to investigate blood pressure lowering effects of folic acid in patients with borderline hypertension.EUCTR2005-000333-38-DEOrganisation name was not entered50
进行中（未招募）
1 期
A study to see whether giving the drug heme-arginate to recipients before kidney transplant can increase the level of a protective protein and protect their transplanted kidney.Ischaemia-reperfusion injury in renal transplantationMedDRA version: 20.1 Level: LLT Classification code 10014646 Term: End stage renal disease (ESRD) System Organ Class: 100000004857MedDRA version: 20.0 Level: LLT Classification code 10023438 Term: Kidney transplant System Organ Class: 100000004865EUCTR2011-004311-23-GBniversity of Edinburgh40
终止
4 期
Can the double orexin receptor antagonist suvorexant increase rapid eye movement (REM) sleep and improve sleep-dependent processing of emotional memories in healthy adults?PTSDMental Health - Other mental health disordersACTRN12619001694101The University of Melbourne30
进行中（未招募）
1 期
Randomized placebo-controlled trial to investigate clinical efficacy, anti-inflammatory properties andsafety of prednisolone in hand osteoarthritis: a proof-of-concept studyHand osteoarthritisEUCTR2015-000687-33-NLeiden University Medical Center90